N/A N=120 The Impact and Benefit of Physical Activity on Premature Ejaculation
Premature Ejaculation
Primary: Premature Ejaculation Diagnostic Tool (Total Score) — 14.5; 13.7; 13.7; 8.9 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=256 Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation
Premature Ejaculation
Primary: Mean Intravaginal Ejaculatory Latency Time (IELT): Change From Baseline to During 3 Month Double Blind-treatment — 4.607; 1.505 ratio — p=<0.0001
N/A N=12 TPTNS for Treating Patients With Premature Ejaculation
Premature Ejaculation
Primary: Clinical Improvement — 8 Participants
Phase 2 N=88 IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)
Premature Ejaculation
Primary: Mean Fold Change in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT) — 2.1; 1.1 No units for fold change
Phase 2 N=77 A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation
Premature Ejaculation
Primary: Mean Intravaginal Ejaculatory Latency Time (IELT) Compared Over All 8 Weeks of Treatment or Until Premature Discontinuation — 0.62; 0.72; 0.69; 0.71 minutes — p=0.4959
Phase 2 N=239 IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)
Premature Ejaculation
Primary: Change From Baseline in Geometric Mean (GM) Intravaginal Ejaculatory Latency Time (IELT) Over the Treatment Assessment Period — 42.6; 39.7; 44.5; 29.2 Seconds
Phase 3 N=495 Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction
Erectile Dysfunction · Sexual Dysfunction
Primary: The Average Intravaginal Ejaculatory Latency Time (IELT) at Week 12 — 1.1; 3.4; 1.1; 5.2 minutes — p=<0.001
N/A N=20 Penile Nerve Stimulation for Treatment of Delayed Ejaculation
Delayed Ejaculation
Primary: International Index of Erectile Function (IIEF) Scale Score — 7.5; 9.7 score on a scale
Phase 3 N=285 The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy
Sexual Dysfunction, Physiological
Primary: The Number of Patients Who Described Their Premature Ejaculation (PE) as At Least "Slightly Better" in Response to Dapoxetine Treatment — 228 Patients
N/A N=150 A Clinical Investigation to Assess the Effectiveness of Benzocaine in NRL Condoms in Healthy Adult Men Who Feel They Ejaculate Too Quickly During Vaginal Sex
Ejaculation Delayed
Primary: To Determine the Effectiveness of Benzocaine of the Test Condom A Compared With the Control NRL Condom at Prolonging Time to Ejaculation — 168.40; 104.46 Seconds
N/A N=90 Outcomes and Efficacy of Ejaculatory Preserving Transurethral Resection of Prostate
Ejaculatory Dysfunction · BPH
Primary: Preservation of Ejaculation — 34; 8 Participants
Phase 2 N=76 A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels
Ejaculatory Dysfunction · Hypogonadism
Primary: Change From Baseline in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Ejaculatory Function Score at 16 Weeks — 3.61; 2.95 units…
N/A N=35 SSRI Effects on Semen Parameters in Men
Healthy
Primary: Semen Volume — 2.55 mL
N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
Phase 4 N=117 A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction.
Erectile Dysfunction
Primary: International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) — 10.96…
Phase 4 N=489 Prospective Sexual Function Study for BPH Subjects
Prostatic Hyperplasia
Primary: Changes From Baseline (BL) in Total Score From the Full Men's Sexual Health Questionnaire (MSHQ) at 12 Months — -0.7; -8.7 Scores on a scale — p=<0.001
Phase 3 N=117 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Alopecia
Primary: Number of Participants With Adverse Events (AE) Related to Sexual Function in the Double-blind Treatment Period — 5; 9 Participants — p=0.27